Dermavant Sci patents expiration
1. Vtama patents expiration
VTAMA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10647649 | DERMAVANT SCI | Process for preparing tapinarof |
Nov, 2038
(15 years from now) | |
| US11597692 | DERMAVANT SCI | Process for preparing tapinarof |
Nov, 2038
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11612573 | DERMAVANT SCI | Topical pharmaceutical compositions |
May, 2036
(12 years from now) | |
| US11617724 | DERMAVANT SCI | Topical pharmaceutical compositions |
May, 2036
(12 years from now) | |
| US11622945 | DERMAVANT SCI | Topical pharmaceutical compositions |
May, 2036
(12 years from now) | |
| US10426743 | DERMAVANT SCI | Topical pharmaceutical compositions |
May, 2036
(12 years from now) | |
| US11458108 | DERMAVANT SCI | NA |
May, 2036
(12 years from now) | |
| US10195160 | DERMAVANT SCI | Topical pharmaceutical compositions |
May, 2036
(12 years from now) | |
| US11590088 | DERMAVANT SCI | Use of Tapinarof for the treatment of chronic plaque psoriasis |
Nov, 2039
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 23, 2027 |
Drugs and Companies using TAPINAROF ingredient
NCE-1 date: 2026-05-23
Market Authorisation Date: 23 May, 2022
Treatment: Topical treatment of plaque psoriasis in adults
Dosage: CREAM;TOPICAL
More Information on Dosage
VTAMA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic